The latest addition to the line of GLP-1/glucagon co-agonist is survodutide (BI 456906), which was recently tested in a phase II trial involving 387 obese participants without T2DM for 46 weeks [177]. This evidence concerns the gene GCG and type 2 diabetes mellitus.